Loading
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Previous close
$11.01
−$0.21 · -1.87%
Pre-market
$11.11
+$0.10 · +0.91%
Oct 9, 5:34 AM ET
Regular session · ET · Market data may be delayed.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Day range
Current $11.01
52-week range
Current $11.01
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
56
Mixed
Risk
64
High Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Day range
Current $11.01
52-week range
Current $11.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.12B USD | 682.16M USD | 556.38M USD | 1.6B USD | 197.58M USD |
| Cost of goods sold | 71.14M USD | 202.74M USD | 343.77M USD | 902.64M USD | — |
| Gross profit | 1.05B USD | 479.42M USD | 212.61M USD | 696.31M USD | 197.58M USD |
| Research and development | 336.82M USD | 391.17M USD | 737.5M USD | 1.24B USD | 2.53B USD |
| Selling, general, and administrative | 150.35M USD | 337.19M USD | 468.95M USD | 488.69M USD | 298.36M USD |
| Operating expenses | 489.07M USD | 728.35M USD | 779.13M USD | 1.34B USD | 1.88B USD |
| Interest expense | 22.55M USD | 20.08M USD | 14.42M USD | 19.88M USD | 21.13M USD |
| Depreciation and amortization | 27.61M USD | 48.5M USD | 41.23M USD | 29.05M USD | 12.66M USD |
| Operating income | 563.27M USD | −248.93M USD | −566.51M USD | −644.74M USD | −1.69B USD |
| Net income | 440.3M USD | −187.5M USD | −545.06M USD | −657.94M USD | −1.74B USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI53.09M0.53%10.11B USD0.35%$149.29-0.63%
Vanguard Morningstar Total Stock Market ETFVTI48.7M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM45.2M0.06%77.7B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB35.45M0.02%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK20.3M0.04%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF17.93M0.02%95.4B USD0.05%$233.13-0.15%
Invesco Biotechnology & Genome ETFPBE13.92M3.37%412.43M USD0.59%$94.065-0.80%
iShares Biotechnology ETFIBB13.3M0.13%10.41B USD0.44%$200.48-1.41%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco Biotechnology & Genome ETFPBEiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
